OrbiMed Advisors LLC, identified as a ten percent owner of Adicet Bio, Inc. (NASDAQ: ACET), disclosed a sale of 104,259 shares of the company's common stock executed on April 7 and April 8, 2026. The transactions produced aggregate proceeds of approximately $674,847, with per-share prices ranging from $6.29 to $6.53.
Transaction detail
- April 7: 29,319 shares sold at $6.53
- April 7: 2,400 shares sold at $6.38
- April 8: 32,523 shares sold at $6.29
- April 8: 40,416 shares sold at $6.52
The combined total of these four tranches equals 104,259 shares. The disclosed proceeds from those trades are approximately $674,847.
Remaining holdings
Following the disposals, OrbiMed Advisors still maintains material indirect exposure to Adicet Bio through multiple affiliated investment vehicles. Those entities include OrbiMed Israel Partners Limited Partnership, OrbiMed Genesis Master Fund, L.P., OrbiMed Private Investments V, LP, and OrbiMed Private Investments VI, LP.
Market context
Adicet Bio's common shares were trading at $6.86 at the time of the report, a level described as near the company's 52-week low of $6.01. The stock has declined roughly 53% over the past six months.
According to analysis cited from InvestingPro, the company may be undervalued at current market levels, with a Fair Value estimate that implies potential upside. The platform also references a comprehensive Pro Research Report available for ACET among its coverage of more than 1,400 U.S. equities.
Analyst activity and clinical program updates
Adicet Bio has seen multiple adjustments to sell-side price targets in recent commentary. H.C. Wainwright at one point increased its target to $50 from $9 on expectations of progress with the company's CD20-targeted allogeneic gamma delta CAR-T therapy, prulacabtagene leucel. That same firm subsequently reduced its target to $27, citing a higher discount rate and larger long-term operating expense assumptions, while maintaining a Buy rating.
Guggenheim also revised its target for Adicet Bio, lowering it from $128 to $100 and keeping a Buy rating. The firm noted strong enrollment momentum in the Phase 1 prula-cel trial, which targets multiple autoimmune indications. Clinical updates for that trial are expected in 2026.
Takeaway
The OrbiMed transactions represent a sale by a substantial investor but do not eliminate the firm's indirect holdings in Adicet Bio. The company's share price sits near recent lows after a marked six-month decline, even as sell-side analysts continue to track clinical progress and adjust valuation assumptions. Investors seeking more granular valuation or research material are directed to platforms that host the referenced Fair Value estimates and Pro Research Report for ACET.